Analysis of gut mycobiota in first-episode, drug-naïve Chinese patients with schizophrenia: A pilot study

Zhang, Xue; Pan, Liya; Zhang, Zhe; Zhou, Yuanyue; Jiang, Hai‐yin; Ruan, Bing

doi:10.1016/j.bbr.2019.112374

Cited by 72 publications

(73 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, alterations in the GMB may play a key role in the etiology and treatment response of SCZ through bacterial infections and contributes to a chronic inflammatory state. The studies by and Zhang et al (2020) found reduced levels of the genera: Roseburia and Faecalibacterium [40,41]. Notably, both genera play an important role in maintaining the intestinal barrier through the production of butyrate [67,68].…”

Section: Evidence For Psychobiotic Intervention In Schizophreniamentioning

confidence: 96%

“…However, both groups were similar in relation to beta diversity. Both studies identified altered levels at various taxa, although there is some discord between these results, most likely due to the low sample size (n = 13) in study by Zhang et al (2020). The phylum Proteobacteria was found to be both increased and similar in abundance in SCZ patients for the two studies [36,43].…”

Section: Acute Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment

et al. 2021

View full text Add to dashboard Cite

The gut microbiome (GMB) plays an important role in developmental processes and has been implicated in the etiology of psychiatric disorders. However, the relationship between GMB and schizophrenia remains unclear. In this article, we review the existing evidence surrounding the gut microbiome in schizophrenia and the potential for antipsychotics to cause adverse metabolic events by altering the gut microbiome. We also evaluate the current evidence for the clinical use of probiotic and prebiotic treatment in schizophrenia. The current data on microbiome alteration in schizophrenia remain conflicting. Longitudinal and larger studies will help elucidate the confounding effect on the microbiome. Current studies help lay the groundwork for further investigations into the role of the GMB in the development, presentation, progression and potential treatment of schizophrenia.

show abstract

Section: Evidence For Psychobiotic Intervention In Schizophreniamentioning

confidence: 96%

Section: Acute Schizophreniamentioning

confidence: 99%

The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…When germ-free mice receive a faecal transplant from a schizophrenia patient, they exhibited schizophreniarelated behaviours [130,131]. In a human study, decreased Faecalibacterium population in Schizophrenia subjects can lead to an increase in gut TH17 cells [132]. These cells has been proposed to activate the microglia in the hippocampus by crossing the blood-brain barrier leading to abnormal behaviour [132] (Table 1).…”

Section: Schizophreniamentioning

confidence: 99%

“…In a human study, decreased Faecalibacterium population in Schizophrenia subjects can lead to an increase in gut TH17 cells [132]. These cells has been proposed to activate the microglia in the hippocampus by crossing the blood-brain barrier leading to abnormal behaviour [132] (Table 1). A study by Zheng et al found that both nontreated and treated patients with schizophrenia had altered gut microbiota, along with the finding that certain bacterial phyla such as Veillonellaceae and Lachnospiraceae were related to disease severity [130].…”

Section: Schizophreniamentioning

confidence: 99%

Gut microbes in neurocognitive and mental health disorders

Halverson

Alagiakrishnan

2020

Annals of Medicine

View full text Add to dashboard Cite

Introduction: As individuals age, the prevalence of neurocognitive and mental health disorders increases. Current biomedical treatments do not completely address the management of these conditions. Despite new pharmacological therapy the challenges of managing these diseases remain.There is increasing evidence that the Gut Microbiome (GM) and microbial dysbiosis contribute to some of the more prevalent mental health and neurocognitive disorders, such as depression, anxiety, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), schizophrenia, bipolar disorder (BP), and dementia as well as the behavioural and psychological symptoms of dementia (BPSD) through the microbiota-gut-brain axis. Methodology: Scoping review about the effect of gut microbiota on neurocognitive and mental health disorders. Results: This scoping review found there is an evolving evidence of the involvement of the gut microbiota in the pathophysiology of neurocognitive and mental health disorders. This manuscript also discusses how the psychotropics used to treat these conditions may have an antimicrobial effect on GM, and the potential for new strategies of management with probiotics and faecal transplantation. Conclusions: This understanding can open up the need for a gut related approach in these disorders as well as unlock the door for the role of gut related microbiota management. KEY MESSAGES Challenges of managing mental health conditions remain in spite of new pharmacological therapy. Gut dysbiosis is seen in various mental health conditions. Various psychotropic medications can have an influence on the gut microbiota by their antimicrobial effect.

show abstract

“…Several researchers have reported that Lachnospiraceae was associated with SZ symptom severity [41,42]. It is also believed that Lachnospiraceae plays a vital role in the inflammation of obesity [43].…”

Section: Discussionmentioning

confidence: 99%

Gut Microbiota Markers for Antipsychotics Induced Metabolic Disturbance in Drug Naïve Patients with First Episode Schizophrenia – A 24 Weeks Follow-up Study

Yuan

Pang

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundWhile cardiometabolic adverse effects associated with antipsychotic treatment is an important clinical challenge, the underlying mechanisms are unknown. Here we investigated if changes in gut microbial composition associate with the metabolic disturbance induced by the risperidone treatment of schizophrenia.MethodsNinety-four first episode, drug naïve schizophrenia patients (SZ), and 100 healthy controls (HCs) were enrolled at baseline. Six metabolic parameters (glucose, homeostasis model assessment of insulin resistance (HOMA-IR), Total cholesterol (Total-C), Low-density lipoprotein cholesterol (LDL-C), High-density lipoprotein cholesterol (HDL-C) and triglycerides) and body mass index (BMI) were measured for all participants. Gut microbial composition (microbials) was determined by fecal samples using 16S ribosomal RNA sequencing. Both the metabolic parameters and the gut microbiota were analyzed at baseline (all participants) and after 12 and 24 weeks of risperidone treatment (patients).ResultsThe glucose was significantly higher in SZ than HCs at baseline (p = 0.005). After 24-weeks treatment with risperidone, the levels of BMI, glucose, HOMA-IR, Total-C, LDL-C, HDL-C and triglyceride, were significant changed compared to baseline (p < 0.01). Six microbials showed significant changes in abundance after 24 weeks of risperidone treatment in SZ (p < 0.05), and four of these (Bacteroidetes, Proteobacteria, Christensenellaceae, and Enterobacteriaceae) were associated with the changes in metabolic parameters (p < 0.05). At baseline, the abundance of the microbials Christensenellaceae and Enterobacteriaceae were significantly associated with changes in triglyceride, BMI and HOMA-IR after 24-week risperidone treatment.ConclusionsChanges in gut microbial composition induced by risperidone treatment may be a key pathway underlying the metabolic disturbances observed in SZ patients. While these findings warrant replication in independent samples, they provide insight into the role of microbiota in SZ treatment, which can form the basis for development of better SZ treatment strategies.

show abstract

Analysis of gut mycobiota in first-episode, drug-naïve Chinese patients with schizophrenia: A pilot study

Cited by 72 publications

References 38 publications

The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment

The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment

Gut microbes in neurocognitive and mental health disorders

Gut Microbiota Markers for Antipsychotics Induced Metabolic Disturbance in Drug Naïve Patients with First Episode Schizophrenia – A 24 Weeks Follow-up Study

Contact Info

Product

Resources

About